Company Overview - Leslie's is the largest direct-to-consumer brand in the pool and spa care industry, with fiscal year 2021 sales exceeding $1.3 billion, representing a 20.7% sales growth[14] - The company's adjusted EBITDA for fiscal year 2021 was $271 million, a 48% increase[14] - Leslie's operates 970 locations across 39 states[24] Market Opportunity - The U S pool and spa aftermarket opportunity is estimated at $14 billion[22, 35] - The addressable market includes 8.7 million residential pools representing a $7.6 billion total addressable market (TAM)[31] - There are 5.5 million addressable spas representing a $2 billion TAM[33] - The professional pool market includes 250,000 commercial pools and 45,000 pool professionals, representing a $4.3 billion TAM[35] Growth & Financial Performance - First half of fiscal year 2022 sales reached $413 million, a 22% increase[82] - The company's first half of fiscal year 2022 adjusted EBITDA grew by 5.5% to $10 million[82] - The PRO business grew by 27% in the first half of fiscal year 2022 and represents approximately 15% of last twelve months (LTM) total sales[85] Fiscal Year 2022 Guidance - Revised fiscal year 2022 sales guidance is between $1.575 billion and $1.61 billion, representing a 17%-20% growth[89] - Revised fiscal year 2022 adjusted EBITDA is projected to be between $315 million and $330 million, a 16%-22% increase[89]

SAN JOSE, Calif., July 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting anti-Müllerian hormone receptor, ...

Novartis wins regulatory approval for the first medicine designed for babies with malaria, marking the latest development in the global fight against the mosquito-borne disease https://t.co/Dfb2TymdUU ...

Key Takeaways CRBG is reinsuring its entire $51 billion variable annuity block in a $2.8 billion deal with CS Life Re. The move will generate $2.1 billion in net distributable proceeds after taxes and reduce tail risk exposure. CRBG boosts share buyback plan by $2 billion, with most proceeds earmarked for repurchases.Corebridge Financial, Inc. (CRBG) recently inked a deal with a subsidiary of Venerable Holdings, Inc., CS Life Re, to reinsure the entire block of variable annuities within its Individual Ret ...

Anixa Biosciences (ANIX) Update Summary Company Overview - Anixa Biosciences was reinvented in 2017 as a biotechnology company focusing on cancer therapies, with a robust pipeline of products currently in clinical trials [5][6] - The company has established partnerships with leading organizations such as the Cleveland Clinic and Moffitt Cancer Center, and receives funding from the U.S. Department of Defense and the National Cancer Institute [6][7] Financial Position - Anixa maintains a strong balance sheet with over two years of cash on hand, allowing for significant clinical milestones without frequent capital raises [8][12] - The company has a clean capital structure with 32 million shares of common stock and no warrants or preferred stock [10][11] Clinical Programs CAR T Therapy for Ovarian Cancer - The CAR T therapy targets terminally ill ovarian cancer patients and is currently in clinical trials at Moffitt Cancer Center [17][19] - The therapy utilizes a unique target, the follicle stimulating hormone receptor (FSHR), which is only found on ovarian cells and tumor blood vessels, allowing for a dual mechanism of action [29][31] - Early results show promising outcomes, with some patients living significantly longer than expected [39][41] - The FDA has approved the possibility of administering a second dose to patients showing initial responses, which is a rare approval for CAR T therapies [41][80] Breast Cancer Vaccine - The breast cancer vaccine aims to treat and prevent breast cancer, particularly targeting triple-negative breast cancer [42][43] - The vaccine is based on the alpha lactalbumin protein, which is produced during lactation and is found in many breast cancer cells [43][44] - Initial Phase I trials have shown strong immune responses and safety, with plans for a Phase II trial to compare the vaccine's effectiveness against standard care [51][55] - The vaccine has the potential to change the paradigm of cancer prevention, aiming for primary prevention in women without a history of cancer [59][60] Market Opportunities - Anixa is addressing large markets, including breast and ovarian cancer, with plans to expand into lung, prostate, and colon cancer [7][20][61] - The company anticipates significant market opportunities if their therapies prove successful, particularly in the context of the breast cancer vaccine [58][61] Strategic Partnerships and Funding - Discussions with potential pharmaceutical partners for both the CAR T therapy and breast cancer vaccine are ongoing, with hopes for fruitful collaborations in the near future [68] - The U.S. Department of Defense has funded the breast cancer vaccine study, recognizing its potential to change cancer treatment landscapes [70][71] Key Milestones and Future Outlook - Upcoming milestones include comprehensive clinical data presentations at the San Antonio Breast Cancer Conference and ongoing updates on patient outcomes for the CAR T therapy [64][66] - The company is optimistic about the potential for partnerships and funding based on the promising early results from their clinical trials [68][86]

Core Insights - Garrett Motion Inc. inaugurated its new Wuhan Innovation Center, enhancing its zero-emission R&D capabilities in China and globally [2][3] - The center is part of Garrett's strategy to strengthen its position as a leader in differentiated automotive technologies, particularly in electrification and decarbonization [3][7] Company Developments - The Wuhan Innovation Center is Garrett's second innovation hub in China, complementing the Shanghai R&D Center to create a "dual innovation engine" [2][5] - The center focuses on high-speed E-Powertrain systems for zero-emission applications, supporting both automotive and industrial decarbonization efforts [5][9] Technological Advancements - Garrett has a history of innovation in mobility technologies, including variable geometry turbines and hydrogen fuel cell compressors, with a strong emphasis on zero-emission solutions [4][6] - The E-Powertrain system integrates an electric motor, inverter, and gearbox, reducing system size and weight by up to 40% and cutting the use of critical materials by approximately 30% [8] Strategic Importance - The Wuhan Innovation Center embodies Garrett's "East for East" strategy, integrating R&D and manufacturing capabilities to accelerate the commercialization of zero-emission technologies [10] - The center aims to attract cross-disciplinary talent and foster partnerships with academic institutions and industry players to drive innovation [10]

Financial Data and Key Metrics Changes - Net revenues declined modestly in Q3, primarily due to a shift in product mix as the new lower ASP Grand Design Transcend series travel trailers outpaced the broader portfolio in terms of units sold [23] - Gross margin decreased by 130 basis points year over year, attributed to higher warranty experience and product mix, partially offset by operational efficiencies [24] - Adjusted EBITDA margin declined by 140 basis points year over year, primarily due to the lower gross margin [24] Business Line Data and Key Metrics Changes - In the Towable RV segment, lower net revenues were largely due to a shift in product mix, with a 2.5% increase in segment unit volume [24] - Motorhome RV results showed a decline in net revenues due to lower unit volume related to market conditions, with total motorhome RV volume down 14.8% compared to the prior year [26] - Marine segment net revenues increased by 15%, driven primarily by higher unit volume and targeted price increases, with unit volume up more than 11% year over year [27] Market Data and Key Metrics Changes - North America RV retail sales declined by 8.2% in April, marking the third consecutive month of retail sales dropping by more than 8% [15] - Wholesale RV shipments increased by 3.4% in April, with towable RVs led by conventional travel trailers rising 4.2% compared to the same month last year [16] - The company lowered its industry forecast for wholesale RV shipments to a range of 315,000 to 335,000 units for calendar year 2025 [18] Company Strategy and Development Direction - The company is focused on executing a comprehensive margin recapture plan centered on refreshing the product line, boosting operational efficiency, and rebuilding sustained profitability beginning in fiscal 2026 [10] - Strategic actions include conducting a capacity utilization analysis, reviewing the manufacturing footprint, and evolving the supply chain in light of expected tariff cost pressure [11] - The company aims to enhance long-term competitiveness and enterprise resilience through disciplined resource allocation and operational efficiency [11] Management's Comments on Operating Environment and Future Outlook - Management noted that growing macroeconomic uncertainty has led to a notable downshift in RV activity, which is expected to continue through the remainder of the calendar year [9] - The company anticipates that the inflection point for recovery in the RV market may not occur as hoped, leading to a tempered outlook for the remainder of calendar year 2025 [50] - Management expressed confidence in the resilience of the brands and the long-term potential of the end markets, driven by the growing appeal of the outdoor lifestyle [35] Other Important Information - The company has been recognized by Newsweek as one of America's most trustworthy companies for the second consecutive year [14] - The company is taking a comprehensive approach to minimize the effects of tariffs, with anticipated modest price increases to offset net remaining exposure of tariffs for fiscal 2025 [30][31] - Free cash flow was negative $81.7 million for the nine-month period, driven primarily by operational inefficiencies and strategic investments [28] Q&A Session Summary Question: Steps being taken to address the Winnebago branded motorhome business - Management discussed significant production reductions to avoid pushing units to the field with high sales allowances, focusing on improving working capital and cash flow [38][39] Question: Profitability decline in the motorized business - Management indicated that the decline is related to deleverage and necessary discounting to push products into the market [44] Question: Outlook for the back half of calendar 2025 - Management refrained from providing specific guidance for calendar year 2026 but acknowledged that the market recovery is not occurring as hoped [50] Question: Impact of tariffs on pricing - Management explained that the anticipated tariff-related costs could lead to price adjustments, with a potential net risk of $0.50 to $0.75 of diluted earnings per share for fiscal 2026 [32][54] Question: Inventory management and turns - Management confirmed that they are targeting a two-turn ratio in the long term, although they do not expect to achieve that by the end of fiscal 2025 [88][92] Question: Performance of Newmar brand - Management highlighted Newmar's strong retail share and profitability, attributing success to a robust product line and effective dealer inventory management [100][102]

Core Insights - Airbus SE has signed a contract with Norwegian Air Ambulance for the delivery of up to eight H145 helicopters, with an initial firm order for two units, which is expected to enhance the company's Helicopters business segment [1][9] - The Helicopters business segment experienced a solid 10% year-over-year revenue growth in Q1 2025 [1][9] Market Demand and Growth - There is a rising global demand for multirole helicopters as defense and civil operators seek versatile and cost-effective platforms for modern warfare, disaster relief, and homeland security [2] - GII Research forecasts a CAGR of 7.1% for the global multirole helicopter market from 2025 to 2035, which presents growth opportunities for Airbus [3] H145 Helicopter Performance - The H145 helicopter is witnessing strong global demand due to its effectiveness in Helicopter Emergency Medical Services and increasing military adoption [4] - The H145M variant features rapid deployment and combat capabilities, with a five-bladed rotor that increases payload by 150 kg, enhancing its operational value [4] Competitor Insights - Boeing's MH-139A Grey Wolf is designed for multi-mission capabilities, with a long-term earnings growth rate of 18.1% and a projected 25.6% sales improvement for 2025 [5][6] - Textron's Bell segment has a long-term earnings growth rate of 10% and a projected 6.6% sales growth for 2025 [6][7] - Lockheed Martin's Sikorsky unit provides military helicopters with a long-term earnings growth rate of 10.5% and a projected 4.7% sales improvement for 2025 [8][10] Stock Performance - Airbus shares have increased by 8.5% over the past month, outperforming the industry growth of 3.4% [11]

Core Viewpoint - Anixa Biosciences, Inc. is set to host an investor webcast on June 26, 2025, to discuss its business strategy, therapeutic portfolio, market opportunities, and upcoming milestones [1][2]. Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention [4]. - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology [4]. - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [4]. - The company partners with renowned research institutions to explore emerging technologies for development and commercialization [4]. Webcast Details - The webcast will feature an introductory presentation by Dr. Amit Kumar, Anixa's Chairman and CEO, followed by a Q&A session for investors [2]. - Interested participants must pre-register to listen to the webcast and ask questions during the live event [3].

那么下一个十年，AI将如何深入塑造我们的生活？互联网精神之父、硅谷预言家凯文·凯利在新作《2049：未来 10000天的可能》中，以2049年为节点，想象了一个AI驱动的高科技社会。 KK预测未来的第一个模型是观察当下富人在做什么，使用什么昂贵服务，并思考哪些事会因为科技的变化而被 大多数人掌握。对富豪而言，由私人秘书来安排自己的工作，由管家来打理自己的生活，这是司空见惯的。 因此，在KK的想象中，到2049年，每个人都会拥有像私人秘书一样的AI助理，它会像GPS导航一样普遍，像电 影《Her》中的助理一样智慧生动。但是未来的交互方式与现在的可能完全不同。 从Apple的Vision Pro、Meta的Aria Gen 2等等智能眼镜设备中，我们已经可以窥见这样的未来。 KKWall by Chris Michel from KK.org 2013年，电影《Her》上映时，观众们还会觉得与主角自然交谈、对答如流的人工智能"Samantha"只是个遥远的 梦想。 而十年后，ChatGPT问世，随之而来的是文心一言、Deepseek、kimi、豆包等众多模型的涌现，人们现在已经习 惯于向AI提问、与之对话、获取知 ...